4 Reasons Investors Are Betting Against Moderna
Moderna (NASDAQ: MRNA) has been developing new drugs for 10 years without a late-stage clinical trial success and a growing number of intrepid short sellers betting the company's dry spell will continue through the end of 2020. The number of Moderna shares sold short passed 28 million on June 15, a 26% increase from the amount sold short at the end of May.
Short-selling is an asymmetrical bet with potentially unlimited losses and gains capped at 100% if a stock goes to zero. Even if your investment thesis is correct, it's important to remember markets can remain irrational much longer than you can remain solvent.
Image source: Getty Images.
Source Fool.com
